Plain-English translation of NCT07323524 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This is a pilot study testing dapagliflozin, a medication originally developed for diabetes, to see if it can help reduce kidney inflammation and protein loss in people with active lupus nephritis. You would take either the medication or a matching placebo pill daily for 12 weeks, along with your regular lupus treatments. The study aims to see if this is a safe and feasible treatment option and whether it helps reduce protein in your urine.
Lupus nephritis can be difficult to control with standard treatments alone, and many patients continue to lose protein in their urine even on therapy. Researchers believe this medication might offer additional kidney protection by working through a different mechanism than current drugs, but this hasn't been tested in lupus patients yet.
You likely qualify if…
You likely don't qualify if…
You would come to the clinic for a screening visit, then a baseline visit to start the study. Over the next 12 weeks, you'd have visits at weeks 4, 8, and 12 to take the pill, check in, and have blood and urine tests. After week 12, the research team would continue collecting information from your routine medical care visits for up to 12 months total. Two-thirds of participants would receive the active medication and one-third would receive placebo, but neither you nor the researchers would know which you're taking.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States